SNGX Soligenix
- 3.3100
- -0.0500-1.49%
About Soligenix Company
Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses on the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.
Company Profile
Company Executives
- Name
- Position
- Salary
- Dr. Christopher J. Schaber,PhD
- Chairman of the Board, Chief Executive Officer and President
- 700.49K
- Dr. Richard Straube, M.D.
- Senior Vice President and Chief Medical Officer
- 249.94K
- Dr. Oreola Donini, PhD
- Chief Scientific Officer and Senior Vice President
- 387.59K
- Jonathan L. Guarino, C.P.A.
- Chief Financial Officer, Principal Accounting Officer, Senior Vice President and Corporate Secretary
- 354.69K
- Gregg Anthony Lapointe, C.P.A.,M.B.A.
- Independent Director
- 77.50K
- Diane L. Parks, M.B.A.
- Independent Director
- 70.00K
- Dr. Robert J. Rubin,M.D.
- Independent Director
- 80.00K
- Dr. Jerome Bernard Zeldis, M.D.,PhD
- Independent Director
- 72.50K
Analysis
Price Target
No Data
No Data